focus -WSS

focus

author：focus 2025-09-29 01:45:29 - browse：39

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Researchers explore possible ties between long Covid, menopause

WSS

NIH confirmation hearing shows politicization of research

Lawmakers consider Medicare pay reforms for doctors

STAT Summit: Biotech founders on deal

Researchers explore possible ties between long Covid, menopause

Weight loss drugs aren’t covered by Obamacare. That may change

STAT Summit: Michael J. Fox on progress in Parkinson's research

hotspot

focus

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Bright Health sells Medicare Advantage business to Molina

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Drug repurposing or repositioning? The language matters

Surprise medical billing ban raises prices elsewhere

Novavax promises a turnaround & Lilly roils the obesity market

FDA gives detailed accounting of AI

Cancer drug shortages should be causing more outrage

FDA warns medical device makers about rise in fabricated data

hotspot

Researchers explore possible ties between long Covid, menopause

Abridge raises $150m as clinical notes automation market heats up

Ukraine seeks to reclaim its role as a hub for clinical trials

Abridge raises $150m as clinical notes automation market heats up

Secretariat’s lessons for human medicine

STAT Summit: Biotech founders on deal

entertainment

knowledge

focus

focus